Medera’s Successful Heart Trial Enrollment Now Complete
No gene therapy–related serious adverse events have been reported to date across both cohorts in Medera’s Phase 1/2a MUSIC-HFpEF...
Jon Napitupulu
Soleno Announces Successful Pivotal Study Results for Vykat
In a 16-week randomized withdrawal study of 77 individuals with Prader-Willi syndrome (PWS), discontinuation to placebo led to a...
New Drug Combo Enters Phase III Trial for Pancreatic Cancer
In the Phase II portion of HUTCHMED’s randomized Phase II/III study in first-line metastatic pancreatic ductal adenocarcinoma (PDAC), the...
Study Finds Babesia Infection in 24% of Chronic Fatigue Cases
Babesia DNA was detected in 24% of a 50‑patient cohort with at least six months of fatigue and concurrent...
Theriva Gets Positive EMA Advice for VCN-01 Phase 3 Trial
Theriva’s Phase 2b VIRAGE trial in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) reported improvements in overall survival, progression-free survival,...
Breakthrough Trial Offers New Hope for Stargardt Disease
Tinlarebant reduced the growth rate of Stargardt lesions by 35.7% versus placebo over 24 months in the Phase 3...
New Data: Leqembi’s Expanding Benefit for Early Alzheimer’s
Modeled long-term analyses from the Clarity AD open-label extension estimated that continuous lecanemab could delay progression from mild cognitive...
New Hope for APL: Quetzal Starts Phase III QTX-2101 Trial
Quetzal Therapeutics has opened a global, randomized Phase III trial of QTX-2101, an oral arsenic trioxide capsule, in newly...
Kymera to Announce KT-621 Atopic Dermatitis Trial Results
In a Phase 1 study in healthy volunteers, Kymera’s oral STAT6 degrader KT-621 achieved complete STAT6 degradation in blood...
New Hope in NSCLC: Enozertinib’s Powerful CNS Activity
Topline data from ORIC’s Phase 1b study of enozertinib (ORIC-114) in EGFR exon 20–mutated NSCLC show a 67% best...